42 results
424B5
TCRT
Alaunos Therapeutics, Inc.
30 Nov 22
Prospectus supplement for primary offering
5:09pm
to attract and retain qualified employees and key personnel; and
S-7
our expectations regarding the impact of the COVID-19 pandemic, including the expected … expectations regarding the impact of the COVID-19 pandemic, including the expected duration of disruption to key clinical trial activities, limitations
424B5
0b3sfuvq387620xqk7r1
28 Nov 22
Prospectus supplement for primary offering
4:07pm
424B5
sz1c5in gon97onxzlp
7 Sep 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
toz98ql04kxwqvmj2 bz
9 Aug 21
Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates
5:04pm